Advertisement

Cancer Causes & Control

, Volume 14, Issue 5, pp 413–418 | Cite as

Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention

  • Andrew T. Chan
Editorial Commentary

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tangrea JA, Albert PS, Lanza E, et al. (2003) Non-steroidal antiinflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 14: 403-411.Google Scholar
  2. 2.
    Schatzkin A, Lanza E, Corle D, et al. (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342: 1149-1155.Google Scholar
  3. 3.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.Google Scholar
  4. 4.
    Langenbach R, Morham SG, Tiano HF, et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acidinduced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492.Google Scholar
  5. 5.
    DuBois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259-1262.Google Scholar
  6. 6.
    Williams CS, Luongo C, Radhika A, et al. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134-1140.Google Scholar
  7. 7.
    Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996) Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188.Google Scholar
  8. 8.
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.Google Scholar
  9. 9.
    Jacoby RF, Marshall DJ, Newton MA, et al. (1996) Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56: 710-714.Google Scholar
  10. 10.
    Boolbol SK, Dannenberg AJ, Chadburn A, et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560.Google Scholar
  11. 11.
    Barnes CJ, Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114: 873-877.Google Scholar
  12. 12.
    Piazza GA, Rahm AL, Krutzsch M, et al. (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116.Google Scholar
  13. 13.
    Piazza GA, Alberts DS, Hixson LJ, et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915.Google Scholar
  14. 14.
    Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686.Google Scholar
  15. 15.
    Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 59: 3387-3391.Google Scholar
  16. 16.
    Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959.Google Scholar
  17. 17.
    He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.Google Scholar
  18. 18.
    Shureiqi I, Chen D, Lotan R, et al. (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850.Google Scholar
  19. 19.
    Labayle D, Fischer D, Vielh P, et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639.Google Scholar
  20. 20.
    Giardiello F, Hamilton S, Krush A, Piantadosi S (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1231-1235.Google Scholar
  21. 21.
    Steinbach G, Lynch PM, Phillips RK, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.Google Scholar
  22. 22.
    Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404.Google Scholar
  23. 23.
    Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177.Google Scholar
  24. 24.
    Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399.Google Scholar
  25. 25.
    Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM (1996) Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 41: 1319-1326.Google Scholar
  26. 26.
    Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL (1996) Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 5: 955-960.Google Scholar
  27. 27.
    La Vecchia C, Negri E, Franceschi S, et al. (1997) Aspirin and colorectal cancer. Br J Cancer 76: 675-677.Google Scholar
  28. 28.
    Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 2326-2333.Google Scholar
  29. 29.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355-358.Google Scholar
  30. 30.
    Muscat JE, Stellman SD, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847-1854.Google Scholar
  31. 31.
    Muller AD, Sonnenberg A, Wasserman IH (1994) Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 39: 2480-2484.Google Scholar
  32. 32.
    Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81: 62-68.Google Scholar
  33. 33.
    Coogan PF, Rosenberg L, Louik C, et al. (2000) NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 11: 249-255.Google Scholar
  34. 34.
    Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320: 1642-1646.Google Scholar
  35. 35.
    Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146.Google Scholar
  36. 36.
    Thun M, Calle E, Namboodiri M, Heath C (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596.Google Scholar
  37. 37.
    Giovannucci E, Egan KM, Hunter DJ, et al. (1995) Aspirin and the risk of colorectal cancer in women. N Engl JMed 333: 609-614.Google Scholar
  38. 38.
    Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161-166.Google Scholar
  39. 39.
    Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93.Google Scholar
  40. 40.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246.Google Scholar
  41. 41.
    Logan RF, Little J, Hawtin PG, Hardcastle JD (1993) Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 307: 285-289.Google Scholar
  42. 42.
    Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT (1998) Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441-447.Google Scholar
  43. 43.
    Breuer-Katschinski B, Nemes K, Rump B, et al. (2000) Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 61: 129-134.Google Scholar
  44. 44.
    Martin C, Connelly A, Keku TO, et al. (2002) Nonsteroidal antiinflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology 123: 1770-1777.Google Scholar
  45. 45.
    Martinez ME, McPherson RS, Levin B, Annegers JF (1995) Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 4: 703-707.Google Scholar
  46. 46.
    Garcia Rodriguez LA, Huerta-Alvarez C (2000) Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11: 376-381.Google Scholar
  47. 47.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299: 1247-1250.Google Scholar
  48. 48.
    Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220-1224.Google Scholar
  49. 49.
    Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128: 713-720.Google Scholar
  50. 50.
    Greenberg E, Baron J, Freeman D (1993) Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 85: 1593-1596.Google Scholar
  51. 51.
    Baron JA, Cole BF, Sandler RS, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899.Google Scholar
  52. 52.
    Sandler RS, Halabi S, Baron JA, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.Google Scholar
  53. 53.
    Frommel TO, Dyavanapalli M, Oldham T, et al. (1997) Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Clin Cancer Res 3: 209-213.Google Scholar
  54. 54.
    Ruffin MT, Krishnan K, Rock CL, et al. (1997) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89: 1152-1160.Google Scholar
  55. 55.
    Chow HH, Earnest DL, Clark D, et al. (2000) Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev 9: 351-356.Google Scholar
  56. 56.
    Sample D, Wargovich M, Fischer SM, et al. (2002) A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 11: 275-279.Google Scholar
  57. 57.
    Patrono C, Coller B, Dalen JE, et al. (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119: 39S-63S.Google Scholar
  58. 58.
    Reddy BS, Maruyama H, Kelloff G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340-5346.Google Scholar
  59. 59.
    Ricchi P, Pignata S, Di Popolo A, et al. (1997) Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 73: 880-884.Google Scholar
  60. 60.
    Spencer RJ, Melton LJ, 3rd Ready RL, Ilstrup DM (1984) Treatment of small colorectal polyps: a population-based study of the risk of subsequent carcinoma. Mayo Clin Proc 59: 305-310.Google Scholar
  61. 61.
    Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101: 1206-1218.Google Scholar
  62. 62.
    Imperiale TF (2003) Aspirin and the prevention of colorectal cancer. N Engl J Med 348: 879-880.Google Scholar
  63. 63.
    Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156: 1530-1536.Google Scholar
  64. 64.
    Larkai EN, Smith JL, Lidsky MD, Graham DY (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153-1158.Google Scholar
  65. 65.
    Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26: 18-24.Google Scholar
  66. 66.
    The Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325: 1261-1266.Google Scholar
  67. 67.
    Farrell B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54: 1044-1054.Google Scholar
  68. 68.
    Roderick PJ, Wilkes HC, Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35: 219-226.Google Scholar
  69. 69.
    Weil J, Colin-Jones D, Langman M, et al. (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: 827-830.Google Scholar
  70. 70.
    Iso H, Hennekens CH, Stampfer MJ, et al. (1999) Prospective study of aspirin use and risk of stroke in women. Stroke 30: 1764-1771.Google Scholar
  71. 71.
    Curhan GC, Willett WC, Rosner B, Stampfer MJ (2002) Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 162: 2204-2208.Google Scholar
  72. 72.
    Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC (2002) Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 40: 604-608.Google Scholar
  73. 73.
    Fored CM, Ejerblad E, Lindblad P, et al. (2001) Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345: 1801-1818.Google Scholar
  74. 74.
    Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321: 1183-1187.Google Scholar
  75. 75.
    Giardiello FM, Yang VW, Hylind LM, et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059.Google Scholar
  76. 76.
    MMWR (2001) Trends in screening for colorectal cancer-United States, 1997 and 1999. Morb Mortal Wkly Rep 50: 162-166.Google Scholar
  77. 77.
    Hu FB, Manson JE, Liu S, et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91: 542-547.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  1. 1.Gastrointestinal Unit, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Channing Laboratory, Department of Medicine, Brigham and Women's HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations